Work

Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial

Year: 2014

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2014.11.006

Authors: Óscar Juan, Francisco Aparisi, Alfredo Sánchez-Hernández, José Muñoz-Langa, Gaspar Esquerdo, José García-Sánchez, Antonio López, Javier Garde, Vicente Giner

Institutions: Hospital Universitari i Politècnic La Fe, Hospital Virgen de los Lirios, Consorcio Hospitalario Provincial de Castellón, Hospital Universitario Doctor Peset, Hospital Clínica Benidorm, Hospital Arnau de Vilanova, Hospital Universitari Sant Joan D'Alacant, Hospital de Sagunto

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Roche

OpenAlex ID: W2081330516

FWCI: 1.694

Cites: 26

Cited by: 15

Related to: 10